Financial Projections - As of December 31, 2025, Jade Biosciences, Inc. expects to report approximately $336 million in cash, cash equivalents, and investments, which is projected to fund operations into the first half of 2028[4]. - The company has not yet completed its quarter-end financial close process for the quarter ended December 31, 2025, and the reported cash figure is preliminary and subject to change[5]. - The company has not provided specific revenue or earnings guidance in this report[4]. - Jade's independent registered public accounting firm has not audited the preliminary cash figures, and no assurance is provided regarding their accuracy[5]. Corporate Governance - Jade Biosciences is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards[3]. - The company plans to provide updates on its corporate presentation through its website and will not file a Form 8-K for each update[7]. Clinical Trials and Product Development - Forward-looking statements include expectations regarding the clinical trials for product candidates JADE101, JADE201, and JADE301, with timelines for interim data and trial initiation[11]. - Risks associated with the clinical trials include potential delays, adverse events, and the need for regulatory approvals, which may impact the company's product development[11]. - Jade's product candidates are anticipated to have potential therapeutic uses and may become best-in-class therapies, although actual results may vary[11]. Upcoming Events - The company is preparing for the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12–15, 2026[7].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2026 ZENAS BIOPHARMA, INC. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ¨ Written communications pursuant to Rule 425 un ...

Financial Position - As of December 31, 2025, the company's preliminary unaudited cash and cash equivalents were approximately $81.5 million, which increased to $85.6 million after receiving an additional $4.1 million from Tranche A warrants[9]. - The company anticipates that its current cash position will fund operations through early 2027, supporting planned clinical and regulatory milestones for 2026[9]. - The company had 153,372,044 shares of common stock outstanding as of December 31, 2025, with no Tranche A warrants remaining[10]. - The company’s financial information is preliminary and unaudited, subject to completion of financial closing procedures for the fiscal year ended December 31, 2025[17]. Clinical and Regulatory Milestones - The company plans to advance its Revita program through key clinical and regulatory milestones in 2026, focusing on validation in post-GLP-1 weight maintenance[11]. - The anticipated milestones for the Revita program include 6-month randomized data from the REMAIN-1 Midpoint Cohort in late January 2026 and a potential PMA filing in H2 2026[14]. - The Rejuva gene therapy platform is expected to progress toward clinical validation in 2026, with first-in-human dosing of RJVA-001 anticipated in H2 2026, subject to regulatory authorization[12]. - The company is aligning its clinical development with regulatory strategy and real-world implementation considerations for Revita as it moves through a registrational year[11]. - The company has completed Clinical Trial Applications for RJVA-001 in the EU and Australia, setting the stage for expected dosing of first patients in 2026[12]. - The company’s strategic outlook for 2026 includes anticipated clinical and regulatory milestones across its Revita and Rejuva programs[8].

TreeHouse Foods, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2026 (Exact name of registrant as specified in charter) | Commission File Number: 001-32504 | | | --- | --- | | Delaware | 20-2311383 | | (State or Other Jurisdiction | (IRS Employer | | of Incorporation) | Identification No.) | | 2021 Spring Road | | | Suite 60 ...

Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ______ to _______. Commission file number: Sonic Lighting, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0418678 (State or other ...

Compensation and Benefits - The Executive's base salary is set at an annual rate of not less than $450,000, payable in equal installments[8]. - The Executive is eligible for an annual bonus with a target equal to 100% of the base salary, contingent on performance goals[9]. - The Executive will receive an initial long-term award of 1,250,000 shares of restricted common stock under the 2025 Omnibus Incentive Plan[10]. - The Executive is entitled to four weeks of paid time off per calendar year, prorated for partial years[12]. - The Executive will have the right to participate in the Company's employee benefit plans during the term[11]. Termination and Severance - Upon termination without cause, the Executive will receive a severance payment equal to one times the sum of the base salary and target annual bonus[20]. - In the event of termination due to death or disability, the Executive's estate will receive accrued benefits including unpaid base salary and a pro rata annual bonus[17]. - All unvested equity grants will immediately vest upon termination without cause or for good reason[20]. - The Company may terminate the Executive's employment without Cause with 60 days' prior written notice[23]. - The Severance Payment upon a CIC Qualifying Termination shall be equal to two times the sum of the Executive's Base Salary and Target Annual Bonus[23]. - The Pro Rata Annual Bonus will be calculated based on "target" level performance and paid 60 days following the Termination Date[23]. - The Executive may terminate employment without Good Reason with 30 days' prior written notice, receiving only Accrued Benefits[27]. - The payment of Severance Benefits is conditioned upon the Executive's execution of a general release of claims within 52 days following termination[28]. - The Executive is not obligated to seek other employment, and there will be no offset against amounts due from subsequent employment[29]. Confidentiality and Intellectual Property - The Executive agrees to maintain confidentiality regarding Company information during and after employment[31]. - All inventions created by the Executive during employment will belong exclusively to the Company[37]. - The Executive agrees to inform the Company of any conflicts between their work and obligations to preserve confidentiality[41]. - The Executive acknowledges that the restraints imposed are reasonable for the protection of the Company and its Confidential Information[42]. Legal and Tax Considerations - The Company agrees to indemnify the Executive against damages and costs arising from claims related to their service[48]. - The Executive is permitted to report possible violations of federal law without prior authorization from the Company[49]. - The Company shall withhold applicable federal, state, and local taxes from any amounts payable under the Agreement[65]. - The intent of the parties is for payments and benefits under the Agreement to comply with Internal Revenue Code Section 409A[66]. - The Executive's right to receive any installment payments is treated as a series of separate and distinct payments[69]. - Payments that constitute "nonqualified deferred compensation" under Code Section 409A cannot be offset by any other amount unless permitted[70]. - If a payment is deemed a "parachute payment" under Section 280G, it will be reduced to avoid excise tax, ensuring the Executive receives the greater after-tax economic benefit[71]. - The Company will appoint a recognized accounting firm or consultancy to determine necessary reductions to payments that may qualify as "parachute payments"[74]. Definitions and Conditions - "Good Reason" for resignation includes a material reduction in Base Salary or target Annual Bonus opportunity exceeding 10%[81]. - The "Restricted Period" for the Executive is defined as 12 months following the termination of employment[82]. - "Change in Control" excludes the Company's emergence from chapter 11 bankruptcy[78]. - The definition of "Affiliate" includes any entity controlled by or under common control with the Company[75]. - "Disability" refers to eligibility for long-term disability payments under the Company's program[80]. - "Confidential Information" excludes publicly available information and knowledge possessed by the Executive prior to employment[79].

Financial Results Announcement - Horizon Bancorp, Inc. will release its financial results for Q4 2025 after market close on January 21, 2026[4] - A conference call to discuss the Q4 2025 financial results is scheduled for January 22, 2026, at 7:30 a.m. CT (8:30 a.m. ET)[4] - The press release regarding the earnings announcement is attached as Exhibit 99.1[5]

Financial Results - Tesla, Inc. published its press release on January 2, 2026, detailing its financial results[4] Stock Information - The company is listed on the Nasdaq Global Select Market under the trading symbol TSLA[2] Company Classification - Tesla is classified as an emerging growth company, indicating it may have certain reporting exemptions[3]

Financial Guidance - Ironwood Pharmaceuticals expects full-year 2026 LINZESS U.S. net sales of $1.125 to $1.175 billion, up from FY 2025 guidance of $860 to $890 million, reflecting a low single-digit percentage demand growth[6] - Total revenue guidance for FY 2026 is projected at $450 to $475 million, compared to $290 to $310 million for FY 2025[6] - Adjusted EBITDA for FY 2026 is expected to exceed $300 million, significantly higher than the FY 2025 guidance of over $135 million[6] Financial Position - As of Q4 2025, Ironwood ended the quarter with over $200 million in cash and cash equivalents, strengthening its financial position[3] Product Pricing and Sales Strategy - The LINZESS list price was lowered effective January 1, 2026, to enhance patient access and is anticipated to drive higher net sales year-over-year[4] - The anticipated increase in LINZESS net sales is driven by the elimination of the inflationary component of required rebates due to the decrease in list price[4] Clinical Development - Ironwood is on track to initiate a confirmatory Phase 3 trial for apraglutide in the first half of 2026, following a meeting with the FDA[2] Strategic Initiatives - The company is progressing its strategic alternatives review to maximize shareholder value and will provide updates as appropriate[4] Revenue Sources - Ironwood's U.S. collaborative arrangements revenue includes reimbursement from AbbVie for a portion of commercial expenses related to LINZESS sales[6] Financial Reporting - Ironwood does not provide guidance on GAAP net income due to the uncertainty of non-GAAP adjustments impacting financial performance[7]

U.S. SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2025 Commission File No.: 001-04192 (Translation of Registrant's name into English) c/o Room 2302, 23/F, Oriental Center, 31 Wujiang Road, Shanghai, China 200041 (Address of of ice) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. x Fo ...